Investment Institute

Viewpoint Chief Economist

Policy Manoeuvres in the Dark

01 February 2021 (5 min read)

Key points

There is some talk of taking the deposit rate further down in some quarters of the European Central Bank (ECB), to try to stem the recent appreciation of the euro. We argue that the growth differential, fuelled by the divergent performance on vaccination, will actually favour the dollar, especially if more political volatility materializes in Europe.

Some members of the ECB Governing Council are clearly worried by the euro appreciation, to the point of talking up the possibility of cutting the deposit rate further, an instrument which had largely been ignored in the recent policy discussions focused on the PEPP/TLTRO duet providing support to the economy by making fiscal policy financially possible and helping banks. We continue to think that we are very close to the “reversal rate”, i.e. the point beyond which cutting rates does more harm than good, especially since the ECB’s capacity to mitigate the impact of such policy on banks is limited. We are also surprised by the prominence of the exchange rate issue. As of last Friday, the euro has appreciated by less than 3% relative to the ECB forecast for 2021 published on December 10th, which would hardly move the needle for inflation and growth.

In our opinion the pendulum has already swung back on the exchange rate. While we will see volatility as Biden will have to compromise to get his fiscal policy push through, there are many reasons to think the US economy will significantly outperform Europe in 2021, and the push higher in US long-term interest rates should ultimately re-create foreign interest in dollar-denominated assets. Beyond the role of fiscal policy – and the fact that the US economy was in any case more resilient before the Covid winter wave struck – the gap on the sanitary front is also widening. The US is not doing as well as the UK on vaccination, but it is still vastly outperforming Europe.

This goes beyond the exchange rate, or even purely macroeconomic considerations. We are concerned that “lockdown fatigue”, exacerbated by mounting criticism on Brussels’ handling of vaccination procurement, could fuel populist movements which so far did not fare that well in Europe since the start of the pandemic. Early elections can still be avoided in Italy if another coalition contract is found between PD, M5S and Italia Viva. If this base case does not materialize, we will have an important test for Europe in the first half of 2021. The US was the main source of “political volatility” these last few months. Hopefully, Europe will manage to avoid taking up that role now.

Not for Retail distribution

This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.

It has been established on the basis of data, projections, forecasts, anticipations and hypothesis which are subjective. Its analysis and conclusions are the expression of an opinion, based on available data at a specific date. All information in this document is established on data made public by official providers of economic and market statistics. AXA Investment Managers disclaims any and all liability relating to a decision based on or for reliance on this document. All exhibits included in this document, unless stated otherwise, are as of the publication date of this document. Furthermore, due to the subjective nature of these opinions and analysis, these data, projections, forecasts, anticipations, hypothesis, etc. are not necessary used or followed by AXA IM’s portfolio management teams or its affiliates, who may act based on their own opinions. Any reproduction of this information, in whole or in part is, unless otherwise authorised by AXA IM, prohibited.

Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI’s express written consent.

This document has been edited by AXA INVESTMENT MANAGERS SA, a company incorporated under the laws of France, having its registered office located at Tour Majunga, 6 place de la Pyramide, 92800 Puteaux, registered with the Nanterre Trade and Companies Register under number 393 051 826. In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.

In the UK, this document is intended exclusively for professional investors, as defined in Annex II to the Markets in Financial Instruments Directive 2014/65/EU (“MiFID”). Circulation must be restricted accordingly.